Src cDNA Expression Kit (wild type) from Upstate
QuantiGene Plex Reagent Set for Animal/Plant Tissue from Panomics
Lipofectin Reagent from Invitrogen
GIBCO Dulbeccos Phosphate-Buffered Saline (D-PBS) (1X); liquid Contains calcium and magnesium from Invitrogen
Biology Products:(Date:11/30/2009)..., , ROCKVILLE, Md., Nov. 30 /PRNewswire-Fir...d today it has completed enrollment in the Phase I...za (2008/2009 recommended strains) VLP vaccine can...(older adults). This randomized, double-blind, ac...erability and immunogenicity of two different dose...
(Date:11/30/2009)..., , SHANGHAI, Nov. 30 /PRNewswire-A...harmaceutical, biotechnology, and medical-device r...perations in China and the United States,announce...logy Fast 50 China,2009 list for the fifth consecu...ing companies in China,s technology, media, and te...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire/..., will initiate water-soluble carbon nanotube-base... The water-soluble carbon nanotubes, which have fu...gation with cancer drugs, was developed in partner...e conjugated carbon nanotubes serves as a drug del...
(Date:11/25/2009)..., , BOSTON, Nov. 25 Bi...H1N1 virus, genomic data from the 1918 pandemic th...e current H1N1 pandemic, today issued its latest b...ws that the lethality of the H1N1 ("Swine Flu") vi...ring the virus,s current outbreak in the spring of...
Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5